Diagnos Stock Performance
| ADK Stock | CAD 0.31 0.01 3.13% |
The firm shows a Beta (market volatility) of -0.22, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Diagnos are expected to decrease at a much lower rate. During the bear market, Diagnos is likely to outperform the market. At this point, Diagnos has a negative expected return of -0.15%. Please make sure to confirm Diagnos' standard deviation and the relationship between the treynor ratio and day median price , to decide if Diagnos performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Diagnos has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest abnormal performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors. ...more
Last Split Factor 1:10 | Dividend Date 2019-04-24 | Last Split Date 2019-04-24 |
1 | DIAGNOS Announces Variation in One Insider Ownership - Yahoo Finance | 09/23/2024 |
2 | SMX Announces Opening of New Facility in Fayetteville, NC - The Manila Times | 11/12/2024 |
3 | Suraksha Diagnostic IPO opens Friday. GMP, price band, key dates among top 10 things to know - The Economic Times | 11/28/2024 |
4 | Suraksha Diagnostic shares list at 1 percent discount over IPO price - The Economic Times | 12/05/2024 |
| Begin Period Cash Flow | 296.6 K | |
| Free Cash Flow | -2.4 M |
Diagnos |
Diagnos Relative Risk vs. Return Landscape
If you would invest 35.00 in Diagnos on September 14, 2024 and sell it today you would lose (4.00) from holding Diagnos or give up 11.43% of portfolio value over 90 days. Diagnos is currently producing negative expected returns and takes up 2.8389% volatility of returns over 90 trading days. Put another way, 25% of traded stocks are less volatile than Diagnos, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Diagnos Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Diagnos' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Diagnos, and traders can use it to determine the average amount a Diagnos' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0538
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ADK |
Estimated Market Risk
| 2.84 actual daily | 25 75% of assets are more volatile |
Expected Return
| -0.15 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Diagnos is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Diagnos by adding Diagnos to a well-diversified portfolio.
Diagnos Fundamentals Growth
Diagnos Stock prices reflect investors' perceptions of the future prospects and financial health of Diagnos, and Diagnos fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Diagnos Stock performance.
| Return On Equity | -24.52 | ||||
| Return On Asset | -1.34 | ||||
| Operating Margin | (15.76) % | ||||
| Current Valuation | 30.21 M | ||||
| Shares Outstanding | 95 M | ||||
| Price To Earning | (2.76) X | ||||
| Price To Book | 54.61 X | ||||
| Price To Sales | 180.09 X | ||||
| Revenue | 170.16 K | ||||
| Gross Profit | (306.77 K) | ||||
| EBITDA | (2.48 M) | ||||
| Net Income | (3.12 M) | ||||
| Cash And Equivalents | 97.5 K | ||||
| Total Debt | 3.19 M | ||||
| Debt To Equity | 2.12 % | ||||
| Current Ratio | 1.19 X | ||||
| Book Value Per Share | (0.04) X | ||||
| Cash Flow From Operations | (2.41 M) | ||||
| Earnings Per Share | (0.04) X | ||||
| Market Capitalization | 29.45 M | ||||
| Total Asset | 663.79 K | ||||
| Retained Earnings | (50.65 M) | ||||
| Working Capital | (1.22 M) | ||||
About Diagnos Performance
Evaluating Diagnos' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Diagnos has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Diagnos has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 14.11 | 13.41 | |
| Return On Tangible Assets | (4.70) | (4.47) | |
| Return On Capital Employed | 2.80 | 2.66 | |
| Return On Assets | (4.70) | (4.47) | |
| Return On Equity | 1.02 | 1.02 |
Things to note about Diagnos performance evaluation
Checking the ongoing alerts about Diagnos for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Diagnos help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Diagnos generated a negative expected return over the last 90 days | |
| Diagnos has some characteristics of a very speculative penny stock | |
| Diagnos has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 170.16 K. Net Loss for the year was (3.12 M) with loss before overhead, payroll, taxes, and interest of (306.77 K). | |
| Diagnos has accumulated about 97.5 K in cash with (2.41 M) of positive cash flow from operations. | |
| Roughly 14.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Suraksha Diagnostic shares list at 1 percent discount over IPO price - The Economic Times |
- Analyzing Diagnos' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Diagnos' stock is overvalued or undervalued compared to its peers.
- Examining Diagnos' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Diagnos' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Diagnos' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Diagnos' stock. These opinions can provide insight into Diagnos' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Diagnos Stock Analysis
When running Diagnos' price analysis, check to measure Diagnos' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Diagnos is operating at the current time. Most of Diagnos' value examination focuses on studying past and present price action to predict the probability of Diagnos' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Diagnos' price. Additionally, you may evaluate how the addition of Diagnos to your portfolios can decrease your overall portfolio volatility.